Document › Details
AdvanceCor GmbH. (8/15). "Press Release: AdvanceCor GmbH Closes a Second Financing Round with MIG AG as Lead Investor". Munich/Martinsried.
|Organisation 2||MIG Verwaltungs AG|
|Group||MIG Fonds (Group)|
|Product 2||venture capital|
|Index term||AdvanceCor–SEVERAL: investment, 201508 2nd financing round €2.2m led by MIG AG inkl Bayern Kapital + Bio-M + HTGF + KfW Bank + founders|
|Person||Münch, Götz (Corimmmun 200701 Managing Director + Co-founder before Procorde)|
|Person 2||Motschmann, Michael (MIG Funds 200604)|
The biotech company AdvanceCOR GmbH has successfully closed a further financing round with MIG AG, Bayern Kapital, Bio-M, Hightech-Gründerfonds and KfW bank, amounting to EUR 2.2 million. The company is specialized in inflammatory mechanisms in cardiovascular diseases. This investment will enable AdvanceCOR to achieve further patient studies with the lead product, the platelet inhibitor Revacept®. Up to date, 53 patients have been included and fully dosed in the current phase II study in symptomatic carotid artery stenosis – no relevant adverse effects have so far been observed. Due to the blinded study design, the analysis of efficacy will be done at the end of the trial. The product pipeline will be further expanded and developed. Revacept® is a lesion-specific inhibitor of arterial thrombosis for the treatment of patients with acute coronary syndromes and stroke. Revacept® has the unique feature to potently inhibit the initial steps of platelet activation without affecting general hemostasis.
The lead investor in this financing round is MIG AG, Munich, Germany. Co-investors in the investor consortium are Bayern Kapital, Bio-M, Hightech-Gründerfonds, the founders and KfW Bank.
Both investors, led by MIG AG, and the founders of the company expressed their content about closing the deal. “The present investment will enable further clinical development of projects. We continue to be confident to bring the company to success in a concerted manner with our shareholders.”
About AdvanceCOR GmbH
AdvanceCOR GmbH is a privately owned biotechnology company located in Martinsried near Munich, Germany. AdvanceCOR owns several clinical and preclinical projects generated from its own scientific program or from the outstanding university groups of the company´s founders.
About MIG AG
MIG Verwaltungs AG is a Munich-based venture capital firm with an investment focus on early to mid stage life science and technology companies in German-speaking Europe. MIG Verwaltungs-AG is the management entity of several venture capital funds (MIG Funds) with a total volume exceeding EUR 800 million. MIG and MIG’s investment portfolio can be found @ www.mig.ag
For more information please contact
Prof. Dr. Götz Münch
Telefon +49-89-2000 204 10
MIG Verwaltungs AG
Ismaninger Straße 102
Telefon +49-89- 98 57 06
Record changed: 2016-04-30
More documents for AdvanceCor GmbH
-  AdvanceCor GmbH. (4/13). "Press Release: AdvanceCor Successfully Starts a Clinical Phase II Trial with Revacept for the Treatment of Ischemic Stroke". Martinsried....
-  AdvanceCor GmbH. (3/13). "Press Release: AdvanceCor GmbH Closes a EUR 6.5 Million Financing Rund with MIG AG as Lead Investor". Munich....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)